Darren Geyer, MD
Family Medicine · Austin, TXNPI 1053311985
Payments from drug & device makers
Across 469 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Amgen$568
- AstraZeneca$550
- Lilly USA, LLC$543
- GSK$413
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,032100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $1,332 |
| Novo Nordisk | 120 | $1,294 |
| Amgen | 27 | $568 |
| AstraZeneca | 33 | $550 |
| Lilly USA, LLC | 30 | $543 |
| GSK | 24 | $413 |
| Pfizer | 16 | $269 |
| Boehringer Ingelheim | 16 | $266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $165 |
| Ironshore Pharmaceuticals Inc. | 5 | $154 |
| Gilead | 8 | $143 |
| Amarin Pharma, Inc. | 7 | $122 |
| Novartis | 8 | $113 |
| Dexcom, Inc. | 4 | $97 |
| Abbott | 5 | $96 |
| Bayer | 4 | $72 |
| Astellas Pharma US Inc | 4 | $71 |
| Genentech USA, Inc. | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Johnson & Johnson | 2 | $44 |
| Mylan Specialty L.p. | 2 | $44 |
| Corcept Therapeutics | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $21 |
| Medtronic | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Radius Health, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,032 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 204 | $228,497 |
| MounjaroTirzepatide | 139 | $144,957 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 87 | $96,182 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $92,036 |
| JardianceEmpagliflozin | 72 | $90,986 |
| FarxigaDapagliflozin Propanediol | 80 | $83,558 |
| EliquisApixaban | 74 | $72,408 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $48,701 |
| ProliaDenosumab | 27 | $46,282 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $38,106 |
| XareltoRivaroxaban | 22 | $31,169 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $29,498 |
| TrulicityDulaglutide | 19 | $27,761 |
| LinzessLinaclotide | 15 | $19,169 |
| NucyntaTapentadol Hcl | 17 | $12,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $1,294 | $242,646228 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $266 | $196,928173 claims |
| Lilly USA, LLCMounjaro, Trulicity | $543 | $172,718158 claims |
| AstraZenecaFarxiga, Symbicort | $550 | $94,640105 claims |
| PfizerEliquis | $269 | $72,40874 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $413 | $58,43962 claims |
| AmgenProlia | $568 | $46,28227 claims |
| Johnson & JohnsonXarelto | $44 | $31,16922 claims |
| AbbVieLinzess, Synthroid | $1,332 | $25,653104 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $10,94316 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $6,143422 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $260 | $5,63612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.